Letters to the Editor
Acrocyanosis after neoadjuvant ipilimumab plus nivolumab: a case report
I.L. Reijers1, M. Hilhorst2, M. Tan3, P.L. Klarenbeek4, A.E. Hak5, C.U. Blank6
- Department of Medical Oncology, and Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Department of Rheumatology and Clinical Immunology, and Department of Internal Medicine, Amsterdam UMC, the Netherlands.
- Department of Internal Medicine, Amsterdam UMC, the Netherlands, the Netherlands.
- Department of Rheumatology and Clinical Immunology, Amsterdam UMC, the Netherlands.
- Department of Rheumatology and Clinical Immunology, Amsterdam UMC, the Netherlands.
- Department of Medical Oncology, and Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands. c.blank@nki.nl
CER12841
2020 Vol.38, N°5
PI 1031, PF 1032
Letters to the Editor
Free to view
(click on article PDF icon to read the article)
PMID: 32301417 [PubMed]
Received: 07/10/2019
Accepted : 03/02/2020
In Press: 17/04/2020
Published: 02/10/2020
